Health Canada stepped up to the plate back in December with a Notice of Intent to amend the Food and Drug Regulations and the Narcotic Control Regulations to restore…
FH.NEO
$41.189M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has received approval from Health Canada for a Phase 2 clinical trial utilizing the Company’s standardized natural psilocybin…
You’d be hard pressed to find someone who hasn’t been touched by depression or anxiety. Biochemically, they’re considered co-morbid, which means they often happen at the same time and…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Quite the price action on Filament Health yesterday. The company is all about paving the way for the first ever natural psychedelic drug. Filament Health Corp. operates as a…
Psychedelics have showed tremendous potential in treating neurological conditions such as major depressive disorder, PTSD, ALS, and generalized anxiety. Investors jumped on the opportunity, sending market values skyrocketing. It’s…
The world’s first psychedelic ETF, PSYK, is an industry bellwether which indicates the psychedelics space continues to take a drubbing since the ETF launched in January. The fund closed…
Filament Health Corp. (FH.NE) (“Filament”) announced today that it will be participating in three conferences throughout December 2021. These conferences include the Horizons: Perspectives on Psychedelics Conference, H.C. Wainwright 2nd…
Filament Health Corp. (FH.NE) announced today that it has entered into a co-development and exclusive licensing agreement with EntheoTech Bioscience Inc. “Our partnership with EntheoTech showcases our commitment to…
Detroit, Michigan city officials announced on Monday that they had decriminalized psychedelics, becoming the latest municipality to pull back on law enforcement when it comes to plant-based mind-manifesting substances….